Ask AI
Advancing Heart Failure Care With MRAs

CE / CME

Advancing Heart Failure Care With Steroidal and Nonsteroidal Mineralocorticoid Receptor Agonists

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: June 17, 2025

Expiration: June 16, 2026

Activity

Progress
1 2
Course Completed

Introduction

In this module, Ty J. Gluckman, MD, MHA, discusses the emerging evidence and evolving role of MRAs as a pillar of GDMT in patients with HFpEF and HFmrEF. Then patient cases illustrate when healthcare professionals (HCPs) should initiate an MRA, including current data on use of steroidal vs nonsteroidal options.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be downloaded here or by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning and once at the end of the activity. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with HF do you provide care for in a typical week?

For those who practice in academic or community settings, please indicate your practice setting:

In your current practice, how often do you prescribe MRAs for patients with HFmrEF or HFpEF?

Which of the following correctly illustrates current treatment of heart failure with mildly reduced ejection fraction (HFmrEF)/heart failure with preserved ejection fraction (HFpEF)?

Based on the latest clinical trials, what is a key safety advantage of finerenone compared to steroidal mineralocorticoid receptor antagonists (MRAs) in patients with HFmrEF/HFpEF?

A 72-year-old woman with HFpEF (left ventricular ejection fraction [LVEF]: 56%), chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR]: 48 mL/min/1.73 m²), hypertension (HTN), and type 2 diabetes (T2D) is symptomatic despite optimal guideline-directed medical therapy (GDMT), including diuretics and an SGLT2 inhibitor. Recent labs show potassium of 4.8 mEq/L. Given the latest clinical trial evidence, what is the most appropriate next step to enhance her heart failure (HF) management?